Objective: To examine long-term care facility (LTCF or nursing home) use and end-of-life care for individuals with Parkinson disease (PD).
Parkinson disease (PD) prevalence will rise sharply in the coming decades because of the aging of the population and improved survivorship. Current data on patients with PD in long-term care facilities (LTCFs), frequently referred to as nursing homes, focus on the PD symptoms (motor dysfunction, cognitive impairment, and psychosis) that predict nursing facility placement. 1, 2 Women and minorities with PD are at increased risk of being diagnosed with dementia, and are also least likely to receive guideline-adherent PD care. 3, 4 However, previous studies have not examined race and sex differences in nursing home placement, which may provide initial evidence of the long-term effects of these observed differences in disease course and treatment quality.
We have previously reported that Medicare beneficiaries with a new PD diagnosis who received regular neurologist care soon after diagnosis had a lower 1-year risk of hip fracture and greater 6-year survival, 5 but the usefulness of specialist care for the highly disabled or those at later stages of PD is unclear. End-of-life care is an integral part of neurology training, and one possible benefit of neurologist care in endstage PD is an out-of-hospital death via use of hospice services for palliative care.
In this study, we describe differences in LTCF utilization among Medicare beneficiaries with PD, decomposing those differences into race and sex disparities, and over-and underutilization predicted by clinical characteristics/ events. We also examine neurologist and palliative care use by LTCF residents, providing initial data for updated PD clinical guidelines that improve outcomes at all stages of the disease. Study design, patient, and clinical characteristics. This retrospective cohort study included 469,055 elderly Medicare beneficiaries with a diagnosis of PD identified in the year 2002 and followed through December 31, 2005. Medicare is a government-mandated insurance and prescription program used by 98% of adults aged 65 years and older, and a portion of the disabled population. Our PD case assessment methods are described elsewhere. 6 Briefly, we identified prevalent PD diagnoses in the Carrier Research Identifiable Files using the ICD-9 codes 332 and 332.0. Those beneficiaries who also had a diagnosis for a Parkinson-plus syndrome, or were younger than the age of standard Medicare eligibility (65 years), were excluded from further analysis.
PD cases were linked with the Beneficiary Annual Summary File, which contains demographic variables (race, age, and sex), data on health service utilization (including hospice, office visits, and hospitalizations), chronic/comorbid conditions, and vital status. Race or ethnicity was categorized using Medicare standard race codes. Beneficiary Annual Summary File Chronic Condition Warehouse 7 data contain the initial diagnosis date for 21 common medical conditions, including the following: congestive heart failure, atherosclerotic heart disease, diabetes, chronic obstructive pulmonary disease, acute myocardial infarction, dementia/cognitive impairment, hip fracture, and chronic kidney disease, and malignancy of the breast, colon/rectum, lung, or prostate, identified using validated ICD-9-based algorithms. These data were used to create an age-weighted Charlson comorbidity score for each patient, and also to examine the relative impact of these conditions on nursing facility placement and hospice utilization.
Provider characteristics. We used the physician specialty code variable in the carrier file to identify the specialties of the physician who provided outpatient PD care. These files allow us to distinguish between practicing neurology or a primary care specialtyinternal medicine, family practice, or geriatrics. A patient with PD was determined to have "neurologist care" if they had at least 2 outpatient office visits for PD with a neurologist between 2002 and 2005, a minimum threshold for quality care of other chronic diseases. 8, 9 Outcomes. There were 2 main outcomes: residential nursing facility care and hospice utilization. To determine place of care, we applied a previously validated algorithm (table 1) that utilizes billing claims and extracted variables describing (1) facility type, (2) place of service, and (3) Current Procedural Terminology codes suggestive of LTCF care/nursing home residence to claims data from the year 2002. 10 We restricted the value for the place of service variable "nursing facility" in order to exclude individuals receiving nursing care in skilled nursing facilities and in the inpatient setting, as these were more likely to be acute care-related (e.g., postoperative skilled nursing facility care). We compared individuals with PD in a nursing facility with those residing in the community according to 3 groups of factors: (1) race, age, and sex; (2) dementia/cognitive impairment diagnosis (yes/no); and (3) presence of comorbid illness and total comorbidity burden.
To examine end-of-life care in PD, we identified all patients with PD who died between January 1, 2003, and December 31, 2005. Hospice enrollment (yes/no) before death was determined for the calendar year of death and compared across categories of neurologist care (yes/no), place of care (nursing home vs community), and demographic characteristics (race, age, sex).
Analytical methods. Logistic regression models were developed to determine the likelihood of nursing facility placement according to categories of race, sex, and age and whether a diagnosis of dementia, congestive heart failure, hip fracture, ischemic heart disease, diabetes, or malignancy was present, adjusting for covariates. A separate set of models examined the associations between demographic (race, sex), clinical, and outpatient PD physician specialty characteristics and hospice enrollment before death. Health care utilization has been shown in many diseases, including PD, to vary by individual socioeconomic status and across small geographical areas. 4 To address potential confounding by location or socioeconomic status, our final models included a previously validated county-level socioeconomic deprivation score, which accounts for small area variation in specialty care access by Medicare beneficiaries driven by socioeconomic characteristics. 11 All models also included an age-weighted modified Charlson comorbidity score.
Statistical analyses. Prevalence ratios (PRs) were calculated to compare baseline characteristics between nursing facility and community-dwelling elderly Medicare beneficiaries with PD, and between those who utilized hospice services before death and those who did not. Continuous variables were compared via 2-sided t test, where appropriate; x 2 tests compared categorical variables. Standard methods were used to produce odds ratios (ORs) with 95% confidence intervals (CIs). Statistical analyses were performed using SPSS Statistics version 21 (IBM Corp., Armonk, NY). These sex and age differences are similar to those found in the general LTCF population, which consists mostly of women (66.2%) and individuals aged 75 years and older (71.8%). 12, 13 Studies have also reported that minorities are underrepresented in the general nursing home population, with black persons having 25% to 50% lower LTCF utilization rates than white persons. [14] [15] [16] We found that African Americans with a PD diagnosis were relatively overrepresented in the LTCF population (5.7% vs 4.8% in the community, p , 0.001). Hispanic individuals were more common in the community PD population (2.1% vs 1.3% in LTCFs, p , 0.001) (table 2) .
Regression models used to investigate the likelihood of nursing home care according to demographic variables also indicated that race was a predictor of nursing home placement among elders with PD: black patients were 34% more likely than white patients to reside in an LTCF, even after adjusting for other sociodemographic characteristics and comorbid disease (adjusted OR [AOR] 1.34, 95% CI 1.30-1.38). This is in stark contrast to studies of institutionalization in the general population, which report that black individuals are up 50% less likely to utilize LTCF care compared with white individuals (AOR 0.50, 95% CI 0.35-0.72). 14 Asian (AOR 0.85, 95% CI 0.77-0.95) and Hispanic (AOR 0.86, 95% CI 0.81-0.92) patients with PD were less likely to reside in a nursing facility (table 3) .
Clinical predictors of nursing facility care in PD. Nursing facility residents had a greater burden of comorbid disease than those in the community, evidenced by higher proportions of congestive heart failure, chronic obstructive pulmonary disease, ischemic heart disease, chronic kidney disease, dementia, and cerebrovascular disease (table 2) . Dementia was diagnosed in 65.9% of LTCF patients with PD (compared with 29.3% of community-dwelling patients with PD; PR 2.25, 95% CI 2.23-2.26). Hip fracture had recently occurred in 12.4% of nursing facility residents with PD compared with 5.1% of community dwellers (PR 2.42, 95% CI 2.37-2.47).
Dementia and hip fracture were predictive of nursing facility care, even after adjustment for potential confounders. Dementia was associated with a 4-fold increase in nursing facility placement (OR 4.69, 95% CI 4.62-4.77; AOR 4.06, 95% CI 4.00-4.12). Recent hip fracture was more than twice as likely among nursing home residents (OR 2.65, 95% CI 2.58-2.71; AOR 2.10, 95% CI 2.04-2.15). The sequelae of atherosclerotic vascular disease-stroke/TIA, ischemic heart disease, and congestive heart failure were associated with modestly increased risks of nursing home placement (table 2) .
Outpatient neurologist care among nursing home residents. In clinical practice, a person with PD is often placed in a nursing home (for PD reasons) when PD nonmotor symptoms, such as hallucinations, psychosis, and dementia, occur or motor symptoms (slowness, stiffness, gait, and balance impairment) (table 4) . The association of race and hospice use may reflect cultural and community influences in health beliefs and behaviors, and race disparities in quality care and patient-centered care, whereas provider-level disparities in end-of-life care may reflect differences in training and experience. Hospice services were provided to 80.7% of nursing home residents receiving neurologist care before death vs 59.8% of those who did not have outpatient neurologist care (x 2 , p , 0.001). A logistic regression model determined that neurologist-treated patients were more than twice as likely to receive hospice care before death (AOR 2.35, 95% CI 2.24-2.47). This difference was robust to adjustment for race, age, sex, comorbidity, hip fracture, and dementia status in additional models (table 4) . DISCUSSION This nationwide study of 469,055 community and nursing home residents with PD examined key life transitions: nursing home placement and end-of-life care. We found that 25% of the Medicare PD population receives nursing home care. African Americans, who have a much lower risk of PD, constitute a relatively large proportion of the PD nursing home population. Dementia and hip fracture predispose to nursing home placement in PD, and the benefits of neurologist care extend to the end of life for patients with PD.
The large number of Medicare beneficiaries who have PD and reside in nursing homes (more than 100,000) has substantial implications for patients and their families, the neurology community, longterm care providers, state and federal budgets, and policymakers. Approximately one-third of expenditures from the Medicaid program, which is jointly funded by state and federal governments, go to funding institutional care for older Americans. Such care is expensive-up to $80,000 per year 12 -and is far more expensive than care from a multidisciplinary team of providers led by a neurologist. For policymakers, the growing burden of PD and other neurodegenerative conditions, notably Alzheimer disease, will require new care models and reimbursement policies. 18 The relatively large proportion of African Americans observed in the PD nursing home population is in contrast to previous studies of the general population that demonstrate a lower incidence of nursing facility use by African Americans. 14 Increased disability among African Americans may suggest accelerated disease progression and higher prevalence of disabling comorbidities. Dementia is more prevalent among older black compared with white individuals in both the PD and general populations, 19 and dementia has been consistently shown to correlate highly with nursing facility care in all races. 20 Common comorbid diseases, such as diabetes mellitus, congestive heart failure, and hypertension, are frequently more severe and poorly managed in African Americans. 21 Therefore, overall health and disability, rather than PD, may be the driving force behind nursing home placement in this population.
Factors contributing to a decreased risk of nursing facility placement in other minorities are less clear, particularly among Hispanics, who are also at greater risk of developing dementia. One study found that Hispanic elders with limited English comprehension were less likely to agree to LTCF placement than their English-speaking counterparts. 22 Asian individuals with PD may be less prone to dementia or have a better baseline health status, although data to this effect are limited. Cultures that are family-focused are frequently nonwhite and often have a more negative view of extended care facilities. 23 A growing body of literature reports that minorities in US nursing homes receive worse care than their white counterparts, and families may opt to keep their loved ones at home for this reason. 24 Another possible explanation of greater LTCF use among African Americans and women with PD is that LTCF placement may be a measureable consequence of known race and sex disparities in the use of basic (physiotherapy or dopaminergic therapy) 25, 26 or advanced (deep brain stimulation surgery) 4 therapies for PD. Studies that focus on disease course in understudied groups and on long-term outcomes associated with lowerquality PD care will quantify the proportion of nursing home placements of patients with PD that could be delayed or prevented.
We have previously reported that improved survival, fewer PD-related hospitalizations, lower health care costs, and greater patient satisfaction scores are associated with neurologist care for PD. However, a recent randomized study that tested the effectiveness of an integrated specialty care model found no benefit for PD-related outcomes after adjustment for PD stage. 27 The differences may lie in the balance of unobservable confounders, or more simply, in the choice of outcomes. A potential barrier to progress in patient care (treatment, services, and preventive interventions) and quality survivorship for PD is that previous clinical research in this population has focused on symptomatic therapies (such as medications for tremor, slowness, rigidity, shuffling gait) and disease-related outcomes (Unified Parkinson's Disease Rating Scale score, disease-related quality of life). Given that there is currently no cure or neuroprotective therapy for PD, it may be more appropriate and informative to take a broader, health services approach to PD care and outcomes, viewing disability and resultant outcomes as avoidable (falls with hip fracture, urosepsis after unrecognized urinary tract infection) or unavoidable (symptomatic Lewy body burden). Taking that perspective, dementia and hip fracture emerge as "tipping point" conditions in our study population-most strongly associated with nursing home placement. Hip fracture in PD may be more immediately responsive to a change in processes of care. The contributors to fall with hip fracture in PD are understudied and complex, but may include avoidance of medications that impair balance and cognition (narcotics, benzodiazepines, hypnotics or sleeping agents, anticholinergic, muscle relaxants) and optimal management of PD motor symptoms. Moreover, that approach provides alternative evidence of the benefits of neurologist care by focusing on death, a universal event, finding neurologist care may improve the process of dying with PD. Future studies will define the extent to which complex care models improve outcomes vs promote overspending without benefit or place patients with PD at risk of harm.
Limitations. All studies that utilize administrative data may be subject to bias because of unknown random or nonrandom errors in coding, and the large sample size may not be sufficient to overcome these biases. We were not able to assess whether PD severity was a primary cause of nursing home placement as opposed to functional disability from other common illnesses (congestive heart failure, dementia, and stroke). The process of application for nursing home care can lead to greater recording of comorbidities, and may bias comorbid disease assessment in LTCF patients. Other unobservable factors in this dataset may influence LTCF or hospice utilization, such as marital status, social support, and market, physician, and institutional factors. 28 Our definition of neurologist care was lenient, based on minimum follow-up care thresholds for other chronic diseases of the elderly, such as chronic obstructive pulmonary disease, congestive heart failure, and preventive care. 8, 9, 29 The dying process among individuals with very frequent neurologist care may differ. Despite these limitations, these data reveal the large-scale use of LTCFs by patients with PD, provide additional evidence of a disparate disease course among African Americans with PD, highlight the unmet need for palliative care in PD, and suggest that the benefit of specialty care for PD extends to the end of life. Future studies of these potential differences in care and outcomes may inform treatment and best practice guidelines for PD.
